Oscotec reports positive results from cevidoplenib phase 2 trial in ITP
Oscotec has reported positive results from the phase 2 clinical trial of its SYK inhibitor cevidoplenib in patients with immune thrombocytopenia (ITP) who did not respond or relapsed after prior therapy. As per the South Korean-based clinical-stage pharma company, cevidoplenib has been studied in a randomized, placebo-controlled trial that featured 61 participants. The mid-stage clinical […]